FDA Pulls Plug on Old Primidone Suspension Forever
Published Date: 1/2/2026
Notice
Summary
The FDA has decided that MYSOLINE (primidone) suspension, 250 mg/5 mL, was taken off the market because it wasn’t safe or effective. This means no new generic versions of this medicine will be approved or sold. Patients and drug makers should note this change to avoid confusion and ensure safety starting now.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
FDA Blocks New Generics for MYSOLINE
The FDA determined that MYSOLINE (primidone) suspension, 250 mg/5 mL, was withdrawn from sale for reasons of safety or effectiveness and will be removed from the Orange Book. As a result, the Agency will not accept or approve abbreviated new drug applications (ANDAs) that refer to this 250 mg/5 mL suspension. This decision was published in the Federal Register on January 2, 2026.
Product Withdrawn Over Contamination Risk
MYSOLINE (primidone) suspension, 250 mg/5 mL, was discontinued in 2001 after antimicrobial effectiveness testing raised concerns about possible contamination, including with Pseudomonas aeruginosa. Before the product could return to market a reformulation would be required (including preservative content acceptance criteria and passing antimicrobial effectiveness testing) and the NDA holder would need to demonstrate safety and effectiveness; no new formulation is approved at this time.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
Previous / Next Documents
Previous: 2025-24195, Procurement List; Proposed Deletions
The government plans to remove several products from its special list that supports nonprofits employing people who are blind or severely disabled. This means items like splitting mauls, shammy cloths, talking calculators, and Navy promo gear might no longer be bought through these groups. If you want to speak up, you’ve got until February 1, 2026, to send your comments—so don’t miss out!
Next: 2025-24197, Prestressed Concrete Steel Wire Strand From Argentina, Colombia, Egypt, Indonesia, Italy, Malaysia, Netherlands, Saudi Arabia, South Africa, Spain, Taiwan, Tunisia, Turkey, Ukraine, and the United Arab Emirates; Institution of Five-Year Reviews
The U.S. International Trade Commission is checking if ending special taxes on prestressed concrete steel wire strand from 16 countries, including Turkey, Argentina, and Italy, would hurt American businesses. They want input from companies and the public by early 2026 to decide if these taxes should stay. This review could impact prices and jobs in the steel and construction industries.